Ocumetics Completes Staff Training for First-In-Human Clinical Study of Accommodating Intraocular Lens
(TheNewswire)
Calgary, Alberta – TheNewswire - July 9, 2025 -Ocumetics Technology Corp. (“Ocumetics” or the “Company”)
OTC (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced
ophthalmic technology, is pleased to announce that it has completed training of the clinical team at itsfirst study site in Mexico City. This training is in preparation forthe upcoming first-in-human (FIH) clinical study of the Ocumeticsaccommodating intraocular lens (the “Ocumetics Lens”).
Dean Burns, CEO of Ocumetics Technology Corp.,emphasized the importance of this milestone, stating, “We areexcited to announce the finalization of our site training protocol - avital step in ensuring the successful launch of our first-in-humanstudy. Meticulous training of surgeons and staff at the clinicalstudy site is key to achievement of optimal outcomes and the higheststandard of care.”
This training marks a critical milestone inOcumetics’ 18-year journey toward regulatory approval of atransformative accommodating intraocular lens technology intended torestore vision for patients undergoing cataract extraction. Thetraining program is designed to ensure that all participating staffmembers are equipped with the specialized skills and knowledgenecessary to implant the Ocumetics Lens with precision andsafety.
The Ocumetics Lens is designed to restore the abilityto see both distant and near objects clearly without glasses followingcataract surgery. The training program covers every phase of theclinical trial process, including pre-operative assessment, lenshandling, surgical technique, and post-operative care. Using proventraining methods, the curriculum ensures successful execution of thefirst clinical study of this novel technology.
With clinical team training completed, and ethicscommittee approval pending, Ocumetics is poised to launch its historicFIH trial—an essential step toward clinical validation and eventualregulatory approval to market the Ocumetics Lens.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company thatis dedicated to developing advanced visioncorrection solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims totransform the field of ophthalmology with state-of-the-art intraocularlenses and other vision-enhancing technologies.
Ocumetics is in the preclinical study phase of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an intraocular lens that fits within the natural lenscompartment of the eye, potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dean Burns Roger Jewett
President and Chief Executive Officer ChiefFinancial Officer
(817) 874-7564 roger.jewett@ocumetics.com
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Corporation mentionedabove. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.
Copyright (c) 2025 TheNewswire - All rights reserved.
